Tevogen Inc. Q2 2026: Net loss $(5.84M), EPS $(1.52) — 10-Q SummaryTradingView·Aug 14 at 04:22 PMTVGN0.00%TVGNW+1.01%
Tevogen Q2 FY26 net loss widens to $5.76 million; operating loss rises to $5.66 millionPUBT·Aug 14 at 04:19 PMTVGN0.00%TVGNW+1.01%
Tevogen amends bylaws to reflect corporate name change to Tevogen IncPUBT·Jul 30 at 07:33 AMTVGN0.00%TVGNW+1.01%
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquiredrttnews·Jul 27 at 10:34 PMFBRX+0.05%TVGNW+1.01%
Tevogen Bio Announces 2026 Annual Meeting of Stockholders | TVGN Stock NewsStockTitan·Jul 13 at 01:15 PMTVGNW+1.01%TVGN0.00%
Tevogen Announces Formation of a Healthcare Services Initiative | TVGN Stock NewsStockTitan·Jun 9 at 06:30 AMTVGN0.00%TVGNW+1.01%
Tevogen Advances Strategic Acquisition Plans With Potential To Add $100 Million In Annual Revenuenasdaq·May 29 at 12:35 AMTVGNW+1.01%TVGN0.00%
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | TVGN Stock NewsStockTitan·May 28 at 03:30 AMTVGNW+1.01%TVGN0.00%
